ACIU vs ADXN
AC Immune SA and Addex Therapeutics Ltd., side by side — 7 fiscal years reported in CHF, drawn from SEC filings.
Most recent reported year
| Metric | ACIU | ADXN |
|---|---|---|
| Revenue | CHF 3.6M | CHF 404,102 |
| Net income | CHF -70.4M | CHF 7.1M |
| Gross margin | · | · |
| Net margin | · | · |
| Return on equity | −89.7% | 130.4% |
| Diluted EPS | −CHF 0.70 | CHF 0.07 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | CHF -70.2M | CHF -5.4M |
| Equity | · | · |
| Net debt / equity | · | · |
| Current ratio | 1.02× | 4.42× |
| Revenue CAGR 5y | · | −31.9% |
| Profit CAGR 5y | · | · |
ACIU bills 8.8× the revenue of ADXN, and ACIU closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
7 years side by side
| Fiscal year | ACIU | ADXN |
|---|---|---|
| FY2024 | CHF 27.3M | CHF 404,102 |
| FY2023 | CHF 14.8M | CHF 1.6M |
| FY2022 | CHF 3.9M | CHF 1.4M |
| FY2021 | CHF 0 | CHF 2.9M |
| FY2020 | CHF 15.4M | CHF 3.6M |
| FY2019 | CHF 110.5M | CHF 2.8M |
| FY2018 | CHF 6.9M | CHF 6.0M |
Bottom line
| Fiscal year | ACIU | ADXN |
|---|---|---|
| FY2024 | CHF -50.9M | CHF 7.1M |
| FY2023 | CHF -54.2M | CHF -10.6M |
| FY2022 | CHF -70.8M | CHF -20.8M |
| FY2021 | CHF -73.0M | CHF -15.4M |
| FY2020 | CHF -61.9M | CHF -12.9M |
| FY2019 | CHF 45.4M | CHF -14.8M |
| FY2018 | CHF -51.0M | CHF -1.6M |
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2024 | +CHF 26,904,898 | ACIU |
| FY2023 | +CHF 13,188,047 | ACIU |
| FY2022 | +CHF 2,512,562 | ACIU |
| FY2021 | −CHF 2,916,308 | ADXN |
| FY2020 | +CHF 11,818,181 | ACIU |
| FY2019 | +CHF 107,693,170 | ACIU |
| FY2018 | +CHF 868,145 | ACIU |
The higher-revenue side has changed between ACIU and ADXN over this period. The gap has widened since the earliest year compared.
7 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ACIU's net margin has been more volatile than ADXN's over the 4 comparable fiscal years — 276.0 percentage points of standard deviation against 236.5.
4 of 9 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between ACIU and ADXN over these 4 fiscal years — ACIU led in 2 and ADXN in 2.
4 of 9 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ADXN's return on equity has been more volatile than ACIU's over the 8 comparable fiscal years — 139.6 percentage points of standard deviation against 17.8.
8 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between ACIU and ADXN over these 8 fiscal years — ACIU led in 6 and ADXN in 2.
8 of 11 comparable fiscal years — a year missing data on either side is not counted.